265 related articles for article (PubMed ID: 19638453)
1. Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death.
Li C; Zang Y; Sen M; Leeman-Neill RJ; Man DS; Grandis JR; Johnson DE
Mol Cancer Ther; 2009 Aug; 8(8):2211-20. PubMed ID: 19638453
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.
Li C; Li R; Grandis JR; Johnson DE
Mol Cancer Ther; 2008 Jun; 7(6):1647-55. PubMed ID: 18566236
[TBL] [Abstract][Full Text] [Related]
3. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
[TBL] [Abstract][Full Text] [Related]
4. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.
Li R; Zang Y; Li C; Patel NS; Grandis JR; Johnson DE
Mol Pharmacol; 2009 May; 75(5):1231-9. PubMed ID: 19246337
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.
Fribley A; Zeng Q; Wang CY
Mol Cell Biol; 2004 Nov; 24(22):9695-704. PubMed ID: 15509775
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.
Allen C; Saigal K; Nottingham L; Arun P; Chen Z; Van Waes C
Clin Cancer Res; 2008 Jul; 14(13):4175-85. PubMed ID: 18593997
[TBL] [Abstract][Full Text] [Related]
7. Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.
Chen Z; Ricker JL; Malhotra PS; Nottingham L; Bagain L; Lee TL; Yeh NT; Van Waes C
Mol Cancer Ther; 2008 Jul; 7(7):1949-60. PubMed ID: 18645005
[TBL] [Abstract][Full Text] [Related]
8. PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.
Kim J; Guan J; Chang I; Chen X; Han D; Wang CY
Mol Cancer Ther; 2010 Jul; 9(7):1977-84. PubMed ID: 20571067
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation.
Li C; Johnson DE
Cancer Lett; 2012 Jan; 314(1):102-7. PubMed ID: 21993018
[TBL] [Abstract][Full Text] [Related]
10. Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane).
Chakravarti N; Myers JN; Aggarwal BB
Int J Cancer; 2006 Sep; 119(6):1268-75. PubMed ID: 16642480
[TBL] [Abstract][Full Text] [Related]
11. p53-targeted lincRNA-p21 acts as a tumor suppressor by inhibiting JAK2/STAT3 signaling pathways in head and neck squamous cell carcinoma.
Jin S; Yang X; Li J; Yang W; Ma H; Zhang Z
Mol Cancer; 2019 Mar; 18(1):38. PubMed ID: 30857539
[TBL] [Abstract][Full Text] [Related]
12. Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma.
Baran-Marszak F; Boukhiar M; Harel S; Laguillier C; Roger C; Gressin R; Martin A; Fagard R; Varin-Blank N; Ajchenbaum-Cymbalista F; Ledoux D
Haematologica; 2010 Nov; 95(11):1865-72. PubMed ID: 20663948
[TBL] [Abstract][Full Text] [Related]
13. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.
Lin YC; Chen KC; Chen CC; Cheng AL; Chen KF
Oral Oncol; 2012 Jul; 48(7):585-93. PubMed ID: 22342571
[TBL] [Abstract][Full Text] [Related]
14. Dihydroartemisinin as a Putative STAT3 Inhibitor, Suppresses the Growth of Head and Neck Squamous Cell Carcinoma by Targeting Jak2/STAT3 Signaling.
Jia L; Song Q; Zhou C; Li X; Pi L; Ma X; Li H; Lu X; Shen Y
PLoS One; 2016; 11(1):e0147157. PubMed ID: 26784960
[TBL] [Abstract][Full Text] [Related]
15. (-)-Epigallocatechin gallate induces Fas/CD95-mediated apoptosis through inhibiting constitutive and IL-6-induced JAK/STAT3 signaling in head and neck squamous cell carcinoma cells.
Lin HY; Hou SC; Chen SC; Kao MC; Yu CC; Funayama S; Ho CT; Way TD
J Agric Food Chem; 2012 Mar; 60(10):2480-9. PubMed ID: 22313388
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas.
Lee TL; Yeh J; Van Waes C; Chen Z
Mol Cancer Ther; 2006 Jan; 5(1):8-19. PubMed ID: 16432158
[TBL] [Abstract][Full Text] [Related]
17. The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4.
Zang Y; Thomas SM; Chan ET; Kirk CJ; Freilino ML; DeLancey HM; Grandis JR; Li C; Johnson DE
Autophagy; 2012 Dec; 8(12):1873-4. PubMed ID: 22995770
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism.
Bullenkamp J; Raulf N; Ayaz B; Walczak H; Kulms D; Odell E; Thavaraj S; Tavassoli M
Cell Death Dis; 2014 Oct; 5(10):e1489. PubMed ID: 25341043
[TBL] [Abstract][Full Text] [Related]
19. Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway.
Li F; Rajendran P; Sethi G
Br J Pharmacol; 2010 Oct; 161(3):541-54. PubMed ID: 20880395
[TBL] [Abstract][Full Text] [Related]
20. Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3.
Leeman-Neill RJ; Wheeler SE; Singh SV; Thomas SM; Seethala RR; Neill DB; Panahandeh MC; Hahm ER; Joyce SC; Sen M; Cai Q; Freilino ML; Li C; Johnson DE; Grandis JR
Carcinogenesis; 2009 Nov; 30(11):1848-56. PubMed ID: 19762335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
